C&EN Whitepaper
Safety first: Assessing drugs early can preclude regulatory and health issues

Brought to you by SEKISUI XenoTech

Every drug begins its journey to the clinic with preclinical testing to help predict whether the compound will work and if there is any risk to the patient. One required aspect of this risk assessment is to look for potential drug-drug interactions (DDI). This ebook will explore the regulatory expectations of drug developers to research DDI potential, the relationship between a drug’s characteristics and DDI risk, the methods available to test those characteristics, and considerations for drug developers to plan and successfully navigate DDI risk assessment.

Key Objectives:
  • Understand the regulatory expectations for drug developers with respect to drug-drug interaction studies, particularly in the investigational new drug application process.
  • Understand the relationship between a drug’s  absorption, distribution, metabolism, and excretion (ADME) characteristics and the risk for drug-drug interactions.
  • Learn about the methods available for testing drug characteristics that could impact the risk for drug-drug interactions.

Brought to you by:
Please complete the form to download the eBook.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy